Skip to main content
. Author manuscript; available in PMC: 2018 Dec 14.
Published in final edited form as: Oncogene. 2018 Jun 14;37(42):5633–5647. doi: 10.1038/s41388-018-0350-9

Figure 6. Preventive efficacy of PRPK inhibitors against cutaneous papillomas and SCC in a late-stage prevention model.

Figure 6

(A) At week 30, dermal blood vessels were photographed, and tissues were collected for H&E staining and IHC to detect phosphorylated PRPK (Ser250) and Ki-67. Scale bars = 100 μm. (B, C) Tumor volume and (D, E) number were measured for 30 weeks. Data represent the mean values ± S.D., and significant differences were determined by one-way ANOVA. The asterisks (**) indicate a significant (p < 0.01) difference compared to the group treated with only SSL (Group 12). (F, G) Western blot analysis to detect phosphorylated PRPK (Ser250), cyclin D1, COX-2 and MMP-9 in chronic SSL-induced cutaneous papillomas and SCCs. Mice were divided into groups as follows: Group 8 = no treatment (n = 5); Group 9 = cream alone (n = 10); Group 10 = 1% rocuronium bromide alone (n = 10); Group 11 = 1% betamethasone 17-valerate alone (n = 10); Group 12 = SSL with cream (n = 15); Group 13 = 0.1% rocuronium bromide with SSL (n = 15); Group 14 = 1% rocuronium bromide with SSL (n = 15); Group 15 = 0.1% betamethasone 17-valerate with SSL (n = 15); and Group 16 = 1% betamethasone 17-valerate with SSL (n = 15).